Live Feeds
● LIVE Updated 18h ago · 20 sources tracked

Why weight-loss drugs don’t work for some people

GLP-1 receptor agonists like Ozempic and Wegovy generally cause users to lose up to 15% of body fat. However, a significant portion of users do not respond to these medications. Effectiveness varies based on genetics, lifestyle, and medical adherence.

RSS Source map (20)

What changed

New data identifies the estimated percentage of non-responders and potential genetic variants.

Live updates

  1. Understanding GLP-1 Weight-Loss Drug Non-Response

    GLP-1 receptor agonists like Ozempic and Wegovy generally cause users to lose up to 15% of body fat. However, a significant portion of users do not respond to these medications. Effectiveness varies based on genetics, lifestyle, and medical adherence.

    What's confirmed:

    • GLP-1 receptor agonists such as Ozempic and Wegovy can lead to an average body fat loss of 15%.
    • These medications were originally created to help patients with type 2 diabetes manage blood sugar.
    • GLP-1 drugs improve insulin sensitivity and stimulate insulin secretion when blood levels are elevated.

    Still unconfirmed:

    • Between 10% and 30% of GLP-1 drug users may be non-responders.
    • Roughly 10% of people may carry specific genetic variants that make GLP-1s less effective.
    • Factors influencing Wegovy effectiveness include treatment duration, lifestyle modifications, medication adherence, and underlying medical conditions.
    confidence 80%